Light induced synthesis of protein drug conjugates for imaging and therapy
The ability to functionalise a biologically active protein with a range of different cargo molecules is crucial to accessing new tools for use in fundamental science and clinical medicine. For instance, antibody-conjugates that gr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CTQ2017-84779-R
NUEVAS HERRAMIENTAS QUIMICAS CON APLICACION EN BIOIMAGEN, BI...
80K€
Cerrado
MAGICBULLET
Peptide Drug Conjugates for Targeted Delivery in Tumor Thera...
4M€
Cerrado
PRE2018-085772
DISEÑO, SINTESIS Y EVALUACION BIOLOGICA DE NUEVAS SONDAS QUI...
93K€
Cerrado
bioTARGET
Bioorthogonal Cascade-Targeting: Directing Drugs into Cells...
1M€
Cerrado
PID2019-104626GB-I00
PLATAFORMAS INNOVADORAS PARA APLICACIONES RADIOFARMACEUTICAS
121K€
Cerrado
Información proyecto PhotoPHARMA
Duración del proyecto: 72 meses
Fecha Inicio: 2021-01-20
Fecha Fin: 2027-01-31
Líder del proyecto
UNIVERSITAT ZURICH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The ability to functionalise a biologically active protein with a range of different cargo molecules is crucial to accessing new tools for use in fundamental science and clinical medicine. For instance, antibody-conjugates that graft reporter molecules including fluorescent tags or radioactive metal ion chelates play vital roles in diagnostic imaging with optical and nuclear medicine techniques like positron emission tomography (PET). State-of-the-art advances in chemotherapy also take advantage of the biophysical properties of antibodies in the design of highly potent antibody-drug conjugates (ADCs) that facilitate specific delivery and uptake of cytotoxic or radiotoxic payloads to disease lesions. Surprisingly, almost all existing methods to produce protein-conjugates rely on thermally-mediated coupling chemistries. In PhotoPHARMA, the goal is to break away from the convention of using heat to drive protein functionalisation by designing new photochemical reagents that are activated by the absorption of light. Light-induced activation has the potential to solve many of the practical issues encountered in the synthesis of radiolabelled antibodies and other protein-conjugates. The work encompasses 4 main Objectives: Objective 1. Explore the biochemical scope of light-induced reactions for bimolecular protein-ligation Objective 2. Synthesis, characterisation and biological studies of photo(radio)labelled antibodies for use in diagnostic imaging and therapy Objective 3. Develop automated technologies for photoradiochemical synthesis of 89Zr-antibodies Objective 4. Establish the GLP-synthesis and Chemistry, Manufacturing and Controls (CMC) for future translation of photoradiolabelled 89Zr-antibodies to the clinic The long-term goals are to facilitate the synthesis and clinical translation of protein-drug conjugates by introducing a radical new technology based on the fast, reliable and automated approach of using light-induced chemistry.